SOPHiA GENETICS Announces Major Expansion in the United States with the Signing of Two Major Integrated Health Systems

Rhea-AI Summary

SOPHiA GENETICS (NASDAQ: SOPH) announced the addition of two major U.S. integrated health systems to its network, expanding use of the AI-native, cloud-based SOPHiA DDM™ across West Coast and Midwest laboratories.

The institutions will initially launch genomic testing for up to 60,000 patients annually, use Enhanced Exome for analysis of over 20,000 genes, and together serve a combined population of nearly one million cancer and rare disorder patients.

Positive

• Capacity to support genomic testing for up to 60,000 patients annually
• Onboards two major U.S. health systems, including a top-10 lab
• Enhanced Exome analytics covering over 20,000 genes
• Combined reach covers nearly one million cancer and rare-disorder patients annually

Negative

• None.

News Market Reaction – SOPH

-1.44%

1 alert

-1.44% News Effect

On the day this news was published, SOPH declined 1.44%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Annual genomic testing volume: up to 60,000 patients annually Genes analyzed: over 20,000 genes Patient population served: nearly one million patients annually

3 metrics

Annual genomic testing volume up to 60,000 patients annually Initial genomic testing rollout across West Coast and Midwest health systems

Genes analyzed over 20,000 genes Enhanced Exome application for full-exome analysis on SOPHiA DDM

Patient population served nearly one million patients annually Combined cancer and rare disorder patients at the two health systems

Market Reality Check

Price: $4.50 Vol: Volume 78,871 vs 20-day a...

low vol

$4.50 Last Close

Volume Volume 78,871 vs 20-day average 361,163 (relative volume 0.22) suggests the pre-news move was on light trading. low

Technical Shares at $4.85 were trading above the $3.91 200-day MA and about 14.91% below the 52-week high of $5.70.

Peers on Argus

SOPH was up about 1.04% pre-news with light volume, while peers were mixed: MNDR...

1 Up

SOPH was up about 1.04% pre-news with light volume, while peers were mixed: MNDR up 5.21%, HCAT and LFMD modestly positive, and CCLD and SLP down. This points to stock-specific rather than broad sector-driven action.

Common Catalyst Both SOPH and peer MNDR had AI-focused healthcare headlines, reflecting ongoing interest in AI-enabled clinical and data platforms.

Historical Context

5 past events · Latest: Jan 15 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 15	Innovation awards	Positive	+0.2%	Multiple BIG Innovation Awards for advanced coatings technologies and sustainability benefits.
Jan 12	Prelim earnings & guidance	Neutral	-2.6%	Preliminary 2025 results, 2026 revenue and EBITDA guidance, and planned CEO transition.
Jan 07	AI oncology partnership	Positive	+4.2%	Strategic collaboration with MD Anderson to co-develop AI-driven oncology NGS tests.
Nov 11	Platform integration	Positive	+6.2%	Integration of MSK-IMPACT and MSK-ACCESS assays on DNBSEQ-T1+ using SOPHiA DDM.
Nov 11	AI co-marketing deal	Positive	+6.2%	Co-marketing of MSK assays with SOPHiA DDM on DNBSEQ-T1+ targeting precision oncology labs.

Pattern Detected

Recent SOPHiA GENETICS headlines tied to AI partnerships and platform integrations have often coincided with positive price reactions, while preliminary financial updates and guidance have seen more muted or slightly negative responses.

Recent Company History

Over the last six months, SOPHiA GENETICS has reported multiple milestones. On Jan 12, 2026 it released preliminary Q4/FY 2025 results, 2026 guidance, and a CEO transition plan. On Jan 7, 2026 it announced an AI-driven precision oncology collaboration with MD Anderson. On Nov 11, 2025 two announcements with Complete Genomics highlighted integration of MSK assays and AI analytics on the DNBSEQ-T1+ platform. These events collectively underline a strategy centered on AI-enhanced, high-throughput precision medicine.

Market Pulse Summary

This announcement highlights SOPHiA GENETICS’ continued US expansion, adding two major integrated he...

Analysis

This announcement highlights SOPHiA GENETICS’ continued US expansion, adding two major integrated health systems that may test up to 60,000 patients annually and perform full-exome analysis on over 20,000 genes. It builds on prior AI- and partnership-driven milestones in oncology and sequencing integration. Investors may focus on how quickly these deployments scale in routine workflows, the impact on revenue growth, and the company’s ability to deepen relationships across this nearly one million-patient population.

Key Terms

genomic, exome, bioinformatics

3 terms

genomic medical

"analyze complex genomic data at scale"

Relating to an organism’s genome — the complete set of DNA instructions that determine traits and biological functions — and to the study or use of that information. For investors, genomic technologies and data underpin diagnostics, targeted medicines, and personalized treatments, shaping potential market size, product timelines, and regulatory risk; think of it as reading an instruction manual to design precise medical products, which can speed innovation but also bring scientific and approval uncertainty.

exome medical

"supports comprehensive full-exome analysis for over 20,000 genes"

The exome is the portion of an organism’s genetic code that carries the instructions for making proteins — like the highlighted pages in a huge instruction manual that contain the actual recipes. It matters to investors because many genetic tests, drug targets and diagnostics focus on these protein-making instructions; finding disease-linked changes there can speed development of treatments, reduce research costs, and drive commercial value.

bioinformatics medical

"Combining advanced bioinformatics, the collective knowledge of a global community"

The use of computer tools and data analysis to organize and interpret large biological datasets, such as DNA, protein or patient information. It matters to investors because it speeds up research, lowers development costs and helps identify promising drug targets, diagnostics or personalized treatments—think of it as using GPS and analytics to find the fastest, most reliable route through vast amounts of lab data.

AI-generated analysis. Not financial advice.

BOSTON and ROLLE, Switzerland, Feb. 10, 2026 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ: SOPH), a global leader in AI-driven precision medicine, today announced the addition of two of the largest U.S. healthcare systems to its network.

The two new institutions, which collectively analyze millions of genetic samples annually, include one of the leading nonprofit, multi-region integrated healthcare systems in the U.S. and a top 10 U.S. health system laboratory. Together, these institutions will leverage the AI-native, cloud-based SOPHiA DDM^™ to analyze complex genomic data at scale.

By adopting SOPHiA DDM^™, the two institutions will initially launch genomic testing for up to 60,000 patients annually across the West Coast and Midwest, enabling faster diagnosis and more personalized care for individuals living with hereditary cancers and rare diseases.

Both health systems will utilize SOPHiA DDM™ for Enhanced Exome, an AI-driven analytics application that supports comprehensive full-exome analysis for over 20,000 genes while enabling the ability to dive deeper into clinically relevant regions. With these capabilities directly embedded into their laboratory workflows, the institutions aim to expedite testing turnaround times, streamline operational costs, and expand internal research and innovation initiatives.

John Carey, Managing Director, North America, SOPHiA GENETICS, said: "Partnering with two of the largest health systems in the U.S. underscores the growing need for AI-powered genomic solutions capable of addressing increasingly complex use cases that can scale without adding operational burden. Combining advanced bioinformatics, the collective knowledge of a global community, and streamlined workflows, our AI enables healthcare institutions to unlock deeper insights."

Going forward, this collaboration positions both organizations with a scalable foundation to support future expansion of AI-driven precision medicine. Each year, these organizations serve a combined population of nearly one million cancer and rare disorder patients nationwide.

SOPHiA GENETICS continues to strengthen its presence in the United States while supporting leading healthcare institutions across some of the most complex areas of precision medicine. The expansion in the region reinforces the company's mission to democratize data-driven medicine by equipping researchers and clinicians with AI-powered solutions that accelerate healthcare innovation and research.

For more information on SOPHiA GENETICS, visit SOPHiAGENETICS.com or connect on LinkedIn. 

About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a cloud-native healthcare technology company on a mission to transform patient care by expanding access to data-driven medicine globally. It is the creator of the SOPHiA DDM™ Platform, which analyzes complex genomic and multimodal data and generates real-time, actionable insights for a broad global network of hospital, laboratory, and biopharma institutions. For more information, visit SOPHiAGENETICS.com and connect with us on LinkedIn.

SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise. The information in this press release is about products that may or may not be available in different countries and, if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact support@sophiagenetics.com to obtain the appropriate product information for your country of residence. 

Forward-Looking Statements
This press release contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding SOPHiA GENETICS future results of operations and financial position, business strategy, products and technology, partnerships and collaborations, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on SOPHiA GENETICS' management's beliefs and assumptions and on information currently available to the company's management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in the company's filings with the U.S. Securities and Exchange Commission. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this press release speak only as of its date. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change in the company's expectations or any change in events, conditions, or circumstances on which such statements are based, unless required to do so by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

View original content to download multimedia:https://www.prnewswire.com/news-releases/sophia-genetics-announces-major-expansion-in-the-united-states-with-the-signing-of-two-major-integrated-health-systems-302683856.html

SOURCE SOPHiA GENETICS

FAQ

What does SOPH announced on February 10, 2026 about U.S. expansion?

SOPH added two large U.S. health systems to its network to scale genomic testing. According to the company, the partnership deploys SOPHiA DDM™ across West Coast and Midwest sites to accelerate diagnosis and expand precision-medicine workflows.

How many patients will SOPH support annually with the new U.S. partnerships (SOPH)?

The partnerships will initially support genomic testing for up to 60,000 patients annually. According to the company, that capacity targets hereditary cancer and rare-disease testing across the participating West Coast and Midwest laboratories.

What is Enhanced Exome and how will SOPH use it with new partners (SOPH)?

Enhanced Exome is an AI-driven full-exome analytics application covering over 20,000 genes. According to the company, it enables deeper analysis of clinically relevant regions integrated directly into laboratory workflows for faster, richer genomic insights.

Which U.S. regions and types of institutions will SOPH serve through this expansion (SOPH)?

The expansion covers laboratories on the West Coast and in the Midwest and includes a nonprofit multi-region integrated system and a top-10 health system lab. According to the company, both institutions will adopt SOPHiA DDM™ for clinical and research use.

What investor-relevant scale does the SOPH expansion claim to achieve?

The company cites a combined served population of nearly one million cancer and rare-disorder patients annually. According to the company, this positions the partnerships as a scalable foundation for broader AI-driven precision medicine growth.